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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S286efﬁcacy and safety of an investigational, proprietary, nano-formulated,
lower dose, oral naproxen formulated at 20% lower dose of standard
naproxen compared with placebo and standard naproxen in a validated
and standardized acute pain model.
Methods: This was a Phase 2, multicenter, randomized, single-dose, active-
and placebo-controlled trial. In total, 253 subjects whowere 18-50 years of
agewere enrolled following extraction of2 thirdmolars (1 ofwhichwas
a fully or partially impacted mandibular third molar) who experienced
moderate to severe pain (a score of 50 mm on a 100 mm Visual Analogue
Scale [VAS]) 6 hours after surgery). Subjects received a single dose of
nano-formulated, lower dose naproxen 200 mg or 400 mg, standard nap-
roxen 250mg or 500mg, or placebo. The primary efﬁcacy endpoint was the
sum of total pain relief (TOTPAR) over 0-12 hours (TOTPAR-12). TOTPAR-8,
time to onset of analgesia, and safety and tolerability were also assessed.
ĂResults: Overall, treatment-emergent AEs occurred in 53.9% (137/254) of
subjects. Treatment-related AEs occurred in 5.1% (13/254) of subjects and
were less frequent in subjects receiving nano-formulated naproxen (1%
combined for both nano-formulations) than standard naproxen (5%
combined for both standard formulations).
Conclusions: Nano-formulated, lower dose, oral naproxen demonstrated
good efﬁcacy, onset of action, and tolerability. The ability to utilize a lower
dose and maintain efﬁcacy could result in an improved tolerability and
safety proﬁle and is in line with the FDA directive to use the lowest
effective dose. Further investigation in Phase 3 trials is warranted.
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MULTIMODALITY IMAGING REVEALS NO SIGNIFICANT DIFFERENCES IN
BONE OR JOINT SPACE WIDTH BETWEEN STATIN USERS AND
NONUSERS: DATA FROM THE OSTEOARTHRITIS INITIATIVE
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Users Nonusers Overall Mod
n n R2
Baseline paBMD ratio 134 194 0.03
Baseline aTb.Sp (mm) 117 160 0.17
Baseline JSW250 (mm) 108 151 0.05
Change paBMD ratio 124 175 0.01
Change aTb.Sp (mm) 116 157 0.01
Change JSW250 (mm) 105 147 0.01
Multiple linear regression models included age, weight, Caucasian, male. paBMD ¼ peria
joint space width at x ¼ 0.250.Purpose: Based on in vitro and animal studies it has been hypothesized
that statins may ameliorate structural changes associated with osteoar-
thritis (OA). Among humans, statin users may have reduced knee OA
incidence/progression compared nonusers but these ﬁndings relied on
semi-quantitative radiographic outcomes. Therefore, we evaluated if
consistent long-term statin use was associated with quantitative structural
characteristics of knees with and without tibiofemoral OA using dual-
energy x-ray absorptiometry (DXA), high-resolution magnetic resonance
(MR) imaging, and radiographs.
Methods: The sample comprised a convenience sample of 592 partici-
pants in the Osteoarthritis Initiative (OAI) progression cohort who at the
30- or 36-month and 48-month OAI visits had 3-tesla MR imaging of the
right knee that included coronal 3D fast imaging with steady state
precession trabecular morphometry sequences and knee DXA scans.
Participants were excluded if they had missing medication inventory
form data at any annual OAI visit (baseline to 48-month follow-up).
Statin users were deﬁned as individuals who reported regularly using
statins at every annual OAI visit. Nonusers were deﬁned as individuals
who never reported statin use at an annual OAI visit. Trabecular
morphometry was assessed with a program with a modiﬁed algorithm
(calcDCN, University of California-San Francisco) to evaluate 4 apparent
peri-articular trabecular morphology measures in the central region of
the peri-articular medial tibia: bone volume fraction, trabecular number,
spacing (atb.sp), and thickness. Knee DXA scans were used to derive
a tibial peri-articular bone mineral density (paBMD) ratio (medial paBMD
divided by lateral paBMD). Location-speciﬁc joint space width (JSW, x ¼
0.250) was assessed at the 24-month and 48-month OAI visits. Longi-
tudinal change was calculated as follow-up minus baseline. JSW change
was determined over 24 months while paBMD and trabecular
morphometry change were based on 18- or 12- month change. Multiple
linear regression models were used to explore the association between
statin use and structural outcomes as well as change in structural
outcomes while controlling for age, body weight, sex, racial background
(Caucasian, not Caucasian). To reduce the number of models, only atb.sp
was analyzed among the trabecular morphometry outcomes since
previous analyses have indicated that atb.sp tends to be the most
responsive and it is derived from the other trabecular measures. Chi-
squares and independent sample t-tests were used to assess differences
in demographic and anthropometric data between statin users and
nonusers. A sensitivity analysis was performed that excluded participants
with a hip-knee-ankle angle < -2 degrees on full-limb radiograph (varus
alignment).
Results: Among 592 participants, 137 (23%) participants were statin users
and 196 (33%) participants were nonusers. Statin users and nonusers had
similar distributions of females (users ¼ 44%, nonusers ¼ 53%, p ¼ .12)
and right knees with no radiographic tibiofemoral OA (Kellgren-Lawrence
0 or 1; users ¼ 29%, nonusers ¼ 29%, p ¼ .96). More users (83%) were
Caucasian than nonusers (71%, p ¼ .01). Body weights were similar
among users (85  15 kg) and nonusers (86  16 kg, p ¼ .35) but users
(67  7 years) were older than nonusers (64  9 years, p < .01).
Consistent long-term statin use was not associated with baseline struc-
tural outcomes or changes in structural outcomes (see Table). A sensi-
tivity analysis that excluded individuals with varus alignment had similar
ﬁndings.
Conclusions: Consistent long-term statin use was not associatedwith JSW,
paBMD, or trabecular morphometry among knees with or without tibio-
femoral OA.el Parameter Estimate for User
(p value) Estimate Standard Error p value
(0.05) -0.016 (0.017) 0.35
(<0.01) 0.245 (0.141) 0.08
(0.02) 0.095 (0.211) 0.65
(0.60) 0.004 (0.007) 0.53
(0.69) 0.052 (0.094) 0.58
(0.65) -0.055 (0.105) 0.60
rticular bone mineral density, aTb.Sp ¼ apparent trabecular spacing, and JSW250 ¼
